• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Orchid Pharma receives EIR from US FDA for Tamil Nadu plant

financialexpressApril 19, 2017

Tag: Orchid Pharma , FDA

Orchid Pharma said the US health regulator has issued establishment inspection report (EIR) for its manufacturing facility in Tamil Nadu.

The company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) based on the successful inspection of the formulation manufacturing facility at Irungattukottai, Orchid Pharma said in a filing to BSE.

"The facility was inspected by the USFDA in December 2016," it added.

Upon completion of an inspection by FDA, an EIR is issued which details inspectional findings.

Previous:Mergermarket releases global PMB trend report

Next:Jubilant Life raises Rs 100 cr by issue of commercial papers

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Orchid Pharma receives EIR from US FDA for Tamil Nadu plant | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Ramantadine( FDA)

Ramantadine( FDA)
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
Ribavirin (FDA)

Ribavirin (FDA)
4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）

4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）
Praziquantel (FDA)

Praziquantel (FDA)
Sirolimus (FDA)

Sirolimus (FDA)
Bumetanide (FDA)

Bumetanide (FDA)
Irinotecan (FDA)

Irinotecan (FDA)
Meclozine HCL (FDA)

Meclozine HCL (FDA)
Hexafluorodianhydride(6-FDA)

Hexafluorodianhydride(6-FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service